S2. Formal assessment of AZD5363 combination indices in response to the addition of various endocrine agents. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

Autor: Lesley-Ann Martin, Mitch Dowsett, Barry R. Davies, Stephen Johnston, Gianmaria Liccardi, Aradhana Rani, Hayley Campbell, Urszula M. Polanska, Nikiana Simigdala, Aurélie Thuleau, Qiong Gao, Elisabetta Marangoni, Stephanie K. Guest, Sunil Pancholi, Ricardo Ribas
Rok vydání: 2023
DOI: 10.1158/1535-7163.22502737
Popis: Cell lines were treated as described with GI50 concentrations of each drug alone or in combination, as indicated in the graphs. For Combination Index Tables shown, each graph cells were treated with AZD5363 and a combination of (A) 4-OHT, (B) fulvestrant and (C) anastrozole over a 6-day period. CIs were derived using Calcusyn software and significance was calculated, as detailed in the Methods.
Databáze: OpenAIRE